Colchicine is an antimitotic agent used to treat gout and Behçet's disease (Cerquaglia et al. 2005, Saleh & Arayssi 2014, Angelidis et al. 2018). It works by decreasing inflammation. Colchicine primarily inhibits tubulin (TUBB) (Lu et al. 2012), preventing microtubule polymerisation and thereby disrupts inflammasome activation, microtubule-based inflammatory cell chemotaxis, generation of leukotrienes and cytokines, and phagocytosis.
The COLCORONA trial conducted by the Montreal Heart Institute (MHI) (https://clinicaltrials.gov/ct2/show/NCT04322682) showed that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization in patients with Covid-19 compared to placebo. Colchinine showed efficacy in preventing the 'cytokine storm' and other complications associated with Covid-19.